SCHEMBL1108522

SCHEMBL1108522

CCN(C[C@@H]1NC(=O)NC1=O)S(=O)(=O)c1ccc(Oc2ncc(F)cn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
HTT P42858 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAPT P10636 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
ALDH1A1 P00352 2/20 0.33
KAT8 Q9H7Z6 2/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1100912 1.00 LMNA (0.43) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1108521 0.88 LMNA (0.34) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1101480 0.88 LMNA (0.34) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1098805 0.88 LMNA (0.52) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1108499 0.88 LMNA (0.52) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1098869 0.83 SMN1; SMN2 (0.51) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1108566 0.83 SMN1; SMN2 (0.51) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1108504 0.82 LMNA (0.53) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1101103 0.82 LMNA (0.53) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL1101147 0.82 LMNA (0.53) LMNAHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LMNA 2791/4885HTT 3958/4885SMN1; SMN2 1262/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LMNA 2791/4885HTT 3958/4885SMN1; SMN2 1262/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 LMNA 2081/4885HTT 4646/4885SMN1; SMN2 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.